Integra Lifesciences (IART -8%) take a hit this morning after announcing late yesterday that it had issued a voluntary recall of certaing products manufactured in its Anasco, Puerto Rico facility. The company expects the recall to affect its revenues and profits for both Q1 and Q2. It now anticipates its Q1 EPS to come in around $0.30 - $0.40 on revenues in the range of $194M - $197M, versus Street expectations for $0.70 on $204M. For Q2, the company sees revenues of $205M - $211M, versus the $219.52M analysts are expecting.
Subscribe for full text news in your inbox